Published in AIDS on March 15, 1997
Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity. J Leukoc Biol (2011) 1.41
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol (1998) 1.27
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest (1999) 1.21
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 1.12
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother (2002) 1.05
Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother (1999) 1.02
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2003) 1.02
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol (2001) 1.00
Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death. J Virol (2002) 0.91
Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res (2010) 0.91
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother (2008) 0.89
Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol (2011) 0.89
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol (2009) 0.88
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol (2001) 0.86
Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 0.84
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob Agents Chemother (2000) 0.83
Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet (2004) 0.83
Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers. Arch Drug Inf (2009) 0.81
Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay. Antimicrob Agents Chemother (2005) 0.81
Development of target-based antineoplastic agents. Invest New Drugs (2000) 0.81
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2007) 0.79
Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity. Expert Opin Drug Metab Toxicol (2015) 0.79
Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol (1999) 0.77
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 0.77
Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol (1998) 0.75
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl) (2015) 0.75
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Cimetidine: interaction with oral anticoagulants in man. Lancet (1979) 4.67
Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet (1996) 3.77
Adverse drug reactions. BMJ (1998) 3.25
Economic evaluation of robot-assisted hysterectomy: a cost-minimisation analysis. BJOG (2014) 3.25
Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. J Clin Microbiol (1993) 2.87
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol (1997) 2.26
Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet (1981) 2.25
Use of systematic reviews of randomised trials by Australian neonatologists and obstetricians. Med J Aust (1998) 2.18
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS (1998) 2.16
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet (1999) 2.10
A case control study of infection with an epidemic strain of multiresistant Salmonella typhimurium DT104 in England and Wales. Commun Dis Rep CDR Rev (1994) 2.04
A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun (1998) 2.02
Comparison of ventricular ectopic activity during 24-hour monitoring and exercise testing in patients with coronary heart disease. N Engl J Med (1975) 1.98
Using discrete choice modelling in priority setting: an application to clinical service developments. Soc Sci Med (2000) 1.97
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception (1979) 1.97
Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 1.97
Computerised protocols for laboratory investigation and their effect on use of medical time and resources. J Clin Pathol (1992) 1.87
The role of physiotherapy in the management of acute neck sprains following road-traffic accidents. Arch Emerg Med (1989) 1.83
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol (1984) 1.82
May mothers given warfarin breast-feed their infants? Br Med J (1977) 1.80
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS (1999) 1.78
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol (1989) 1.71
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother (1997) 1.66
Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet (1983) 1.64
The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol (1987) 1.63
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet (1997) 1.61
Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med (2003) 1.61
Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. Am Heart J (2000) 1.58
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
The organisms reported to cause infective myocarditis and pericarditis in England and Wales. J Infect (1996) 1.54
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
General practice management of illicit drug users in Scotland: a national survey. Addiction (2003) 1.52
Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Clin Infect Dis (1995) 1.51
Crystal structure of the phosphatidylinositol-specific phospholipase C from Bacillus cereus in complex with myo-inositol. EMBO J (1995) 1.49
Use of the Alcohol Use Disorders Identification Test (AUDIT) to determine the prevalence of alcohol misuse among HIV-infected individuals. Int J STD AIDS (2013) 1.46
Cytology and mesenchymal pathology: how far will we go? Am J Clin Pathol (1996) 1.46
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasma. Br J Sports Med (2008) 1.46
Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol (1981) 1.45
In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol (1988) 1.44
Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch Dermatol (1996) 1.44
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J (1976) 1.44
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS (1999) 1.44
The veil of experience: do consumers prefer what they know best? Health Econ (2000) 1.43
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol (1991) 1.42
Comparing different methods of assessing body composition in end-stage renal failure. Kidney Int (2000) 1.42
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS (1996) 1.41
Pulmonary embolism in pregnancy: is nuclear medicine imaging still a valid option? Ir Med J (2008) 1.40
Cost of treating stroke in an Irish teaching hospital. Ir Med J (2003) 1.40
The great pretender returns to Dublin, Ireland. Sex Transm Infect (2001) 1.40
The interaction of antibiotics with synthetic steroids in the rat [proceedings]. Br J Pharmacol (1978) 1.40
Rapid on-site evaluation of axillary fine-needle aspiration cytology in breast cancer. Br J Surg (2012) 1.39
Mother care for children in hospital. Br Med J (Clin Res Ed) (1984) 1.39
Falsely reassuring pulse oximetry in the presence of severe hypoxia. Can J Anaesth (1997) 1.39
Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol (1997) 1.37
Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs (1981) 1.36
Gene expression profiling in the post-mortem human brain--no cause for dismay. J Chem Neuroanat (2001) 1.36
The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother (2004) 1.35
P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS (2001) 1.35
An improved system for the assay of stimulation in mouse mixed leucocyte cultures. J Immunol Methods (1974) 1.35
Interindividual differences in the response to oral anticoagulants. Drugs (1977) 1.34
The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol (1990) 1.34
Menopausal symptoms in Australian women. Med J Aust (1993) 1.32
The burden of alcohol misuse on an inner-city general hospital. QJM (2000) 1.31
Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man. Clin Sci Mol Med (1977) 1.30
Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr (1984) 1.30
Acupressure and prevention of nausea and vomiting during and after spinal anaesthesia for caesarean section. Br J Anaesth (2000) 1.29
Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol (1985) 1.27
Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol (1989) 1.27
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol (1998) 1.25
Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J (1991) 1.24
Bacterial phosphatidylinositol-specific phospholipase C: structure, function, and interaction with lipids. Biochim Biophys Acta (1999) 1.23
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol (2004) 1.23
Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. Health Technol Assess (2010) 1.22
p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol (2003) 1.22
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol (1990) 1.21
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS (1999) 1.21